The Three C's of Customer Experience in Oncology

Posted by Pranav Srivastava on Mar 20, 2019 8:00:00 AM

Malik Kaman co-wrote this blog post with Pranav Srivastava.

During a recent client meeting, a vice president of marketing challenged my perspective on the role of customer experience in oncology. Doesn’t every manufacturer want to achieve the same fundamental customer experience? And if we’re all going for the same thing, how can this be a lever of differentiation?  


>
Read More

What Are the Next Moves When Checkpoint Inhibitors Fail?

Posted by Vikas Verma on Mar 16, 2018 8:00:00 AM

Marie Yurkovich and Malik Kaman co-authored this blog post with Vikas Verma.

Antibodies that target immune checkpoints, like those against programmed cell death-1 (PD-1) or its ligand (PD-L1), have rapidly changed the oncology treatment landscape for multiple tumor types including melanoma, bladder cancer and non-small-cell lung cancer (NSCLC). Opdivo and Keytruda, the flagbearers for anti-PD-1 therapy, have collective sales of more than $8 billion alongside a presence in more than six oncology indications.


>
Read More